BioCentury on BioBusiness,
Judge hammers CellPro
Monday, July 28, 1997
CellPro Inc. came two steps closer last week to losing the market for
its Ceprate SC Stem Cell Concentration System, as an FDA advisory panel recommended
approval of rival Baxter Healthcare Corp.'s Isolex 300 Magnetic Cell Separator System, and
a federal court judge granted an injunction against sales of Ceprate once Isolex is
approved.In a sharply worded ruling, Judge Roderick McKelvie of the U.S.
District Court in Wilmington, Del., ordered CPRO to pay Johns Hopkins University, Becton
Dickinson & Co. and Baxter treble damages of $7 million for willful infringement of
the plaintiffs' patents involving CD34+ stem cell selection technology. He also entered an
injunction against sales of Ceprate after Isolex is approved by the FDA
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]